Coagulation Analyzer Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Clinical Laboratory analyser and Point-of-Care Testing analyser), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated

Coagulation Analyzer Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Clinical Laboratory analyser and Point-of-Care Testing analyser), Test (Prothrombin Time Testing, Fibrinogen Testing, Activated Clotting Time Testing, Activated Partial Thromboplastin Time Testing, D-Dimer Testing, Platelet Function Tests, and Others), Technology (Optical Technology, Mechanical Technology, Electrochemical Technology, and Other Technologies), and End Users (Hospitals, Clinical Laboratories, and Others)

The global coagulation analyzers market is expected to reach US$ 5,910.57 million by 2028 from US$ 3,972.38 million in 2021; it is estimated to grow at a CAGR of 5.9% from 2022 to 2028. The growth of the market is majorly driven by the increasing prevalence of blood disorders and the rising incidence of cardiovascular diseases. However, the high costs and stringent regulations associated with coagulation analysers hamper the market growth.

Increasing Prevalence of Blood Disorders

Coagulation analyser device measures and evaluates the speed of clot formation or clot coagulation. It provides a fast and simple way to accurately measure the levels of blood platelet, thrombolin, and thromboplastin. According to the National Organizations of Rare Disorders, hemophilia A is a common X-linked recessive disorder and the second most common inherited clotting factor deficiency after von Willebrand disease. In the US, ~1 in 5,000 newborn males suffer from hemophilia A. According to the National Library of Medicine (NLM), in 2020, ~30,000–33,000 males were affected by hemophilia in the US. According to the US Department of Health & Human Services, in 2020, ~100,000 Americans had sickle cell disease (SCD), the most-commonly inherited blood disorder. Furthermore, by 2050, the number of people suffering from SCD is expected to grow by ~30%. As per the National Library of Medicine, in 2022, ~1% of all individuals (unselected population) are suffering from von Willebrand disease, i.e., 125 per 1 million. Similarly, in the European Union, 80 million people suffer from blood disorders, ranging from cancer to bleeding disorders, as per research published in NLM in 2020. According to National Organization for Rare Disorders s, in the US, immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affects ~66 adults per 1 million each year. Moreover, in the country, the incidence of ITP in adults is ~3.3 per 100,000/year, while the prevalence is 9.5 per 100,000. Thus, the increasing prevalence of blood disorders is driving the coagulation analysers market growth.

Based on type, the global coagulation analyzers market is bifurcated into clinical laboratory analysers and point-of-care testing analysers. The clinical laboratory analysers segment held a larger share of the market in 2021. However, the point-of-care testing analysers segment is anticipated to register a higher CAGR of 7.20% in the market during the forecast period.

The coagulation analyzers market, by test is segmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, D-Dimer testing, platelets function testing, and others. The prothrombin time testing segment held the largest share of the market in 2021. However, the D-dimer testing segment is anticipated to register the highest CAGR of 6.3% in the market during the forecast period.

The coagulation analyzers market, by technology, is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR of 6.1% in the market during the forecast period.

The coagulation analysers market, by end user, is segmented into hospitals, clinical laboratories, and others. The clinical laboratories segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR of 6.1% in the market during the forecast period.

The World Health Organization (WHO), National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for Disease Control and Prevention (CDC), American Society for Clinical Pathology, American Diabetes Association, and Globocan are among the major primary and secondary sources referred to while preparing the report on the global coagulation analysers market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the coagulation analyzer market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global coagulation analyzer market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.